ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Lymphoproliferative Disorders After Renal Transplantation Along Two Decades: A Large Longitudinal Study.

A. Franco,1 D. Hernandez,2 N. Maruri,3 A. Alonso,4 M. Crespo,5 A. Mazuecos,6 C. Diaz-Corte,7 M. Gentil.8

1Nephrology, Hospital General, Alicante, Spain
2Nephrology, Hospital Carlos Haya, Málaga, Spain
3Nephrology, Hospital Cruces, Bilbao, Spain
4Nephrology, Hospital Universitario, A Coruña, Spain
5Nephrology, Hospital del Mar, Barcelona, Spain
6Nephrology, Hospital Puerta del Mar, Cadiz, Spain
7Nephrology, Hospital General, Oviedo, Spain
8Nephrology, Hospital Virgen del Rocío, Sevilla, Spain

Meeting: 2017 American Transplant Congress

Abstract number: C264

Keywords: Epstein-Barr virus (EBV), Kidney transplantation, Post-transplant lymphoproliferative disorder (PTLD), Survival

Session Information

Session Name: Poster Session C: PTLD/Malignancies

Session Type: Poster Session

Date: Monday, May 1, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

In a longuitudinal study,we evaluated the cumulative incidence of Posttransplant limphoproliferative disorders(PTLD),its relationship with Epstein Barr Virus (EBV),classical risk factors and outcome in 21546 single renal adult recipients transplanted in 21 hospital from 1990 to 2009.Records were censored at death or end of the study,december 31st 2014 to allow at least 5 years posttransplant follow up.A total of 272 recipients(70,9%males,aged 50,6(4,7)years,88% first transplants,97,7% from deceased donors)developed PTLD( 1,2%)8.18 cases(8.16,8.19)/10.000 patients/year.PTLD occurred 42 months posttransplant (IQR 12-77,5),81.7 in recipients tested EBV+ in tissue(IQR 25-129)and 82.8 in EBV-(IQR 41-109) (P:0.725).Cumulative incidence was 1,7[permil],5,7[permil] and 10,5[permil] at 1, 5 and 10 years posttransplant.The highest incidence per year was 1,4[permil] the first year,being under 1[permil] the following years. At diagnosis the recipients received cyclosporine(58,8%), FK(35,4%),micophenolate(40,3%), azathioprine(22,6%)and steroids(83.1%) .EBV in tissue was reported in 94 out of the 155 tested recipients(60.6%)and 86.0% were B cell lymphomas .One hundred eighty-eight recipients(69.1%)showed classical risk factors being antilymphocyte antibodies treatment the most frequent.During follow-up,172 patients died(63,2%)and 100 (36,7%)had complete remission, 20 of them losing their grafts(20%).The main cause of death was PTLD progression(n=91, 52,9%),followed by sepsis(n=24,13,9%).Median follow-up of recipients with PTLD was 12 months after diagnosis(1-226months).Patient survival after PTLD was 53%,46% and 40% at 1, 2 and 5 years.and graft survival was 48%, 39% and 33%.In conclusion,PTLD in kidney transplant recipients are mainly B cell proliferations in close relationship with EBV.There is no relation between EVB in tissue and appearence after transplant.They usually develop in the presence of classical risk factors,mainly the use of antilymphocyte antibodies.Although PTLD incidence is low,prognosis at 1 year is poor ,primarily due to PTLD progression, but survivors can even mantain their grafts.

CITATION INFORMATION: Franco A, Hernandez D, Maruri N, Alonso A, Crespo M, Mazuecos A, Diaz-Corte C, Gentil M. Lymphoproliferative Disorders After Renal Transplantation Along Two Decades: A Large Longitudinal Study. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Franco A, Hernandez D, Maruri N, Alonso A, Crespo M, Mazuecos A, Diaz-Corte C, Gentil M. Lymphoproliferative Disorders After Renal Transplantation Along Two Decades: A Large Longitudinal Study. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/lymphoproliferative-disorders-after-renal-transplantation-along-two-decades-a-large-longitudinal-study/. Accessed June 3, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences